Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 600x60px

News > France & Monaco

Please find below news from France and Monaco as well as about organisations from these countries.

Total search results: 1485 | Ordered by Source (descending)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15  next pagenext page

order ascendingorder descendingSource order ascendingorder descendingDate
[iito] Business Intelligence. (10/5/15). "Press Release: Life-Sciences-France.com Launches Today. New Business Web Portal for the French Life Sciences Targets Decision Makers Worldwide". Bremen & Paris. 2015-10-05
Yposkesi. (7/9/18). "Press Release: Yposkesi Appoints Dr. Fraser Wright as Senior Advisor". Corbeil-Essonnes. 2018-07-09
Ynsect S.A.. (3/4/14). "Press Release: Ynsect Raises 1.8 Million Euro in Series A Funding to Develop Insect Biorefineries". 2014-03-04
Ynsect S.A.. (2/21/19). "Press Release: Ÿnsect Raises $125m to Become World Leader in Alternative Protein". Paris & London. 2019-02-21
Ynsect S.A.. (12/17/14). "Press Release: Ynsect Raised 5.5 Million Euros During Its Second Funding Campaign". 2014-12-17
Wyatt Technology Corporation. (11/16/10). "Press Release: Wyatt Technology Instrumentation Used against Bacteriophage Infections in Dairy Production". Santa Barbara, CA. 2010-11-16
Waters Corporation. (6/17/13). "Press Release: Waters Acquity UPC2 System Wins Green Innovation Prize". Amsterdam. 2013-06-17
Vygon S.A.. (9/2/14). "Press Release: Vygon Group Buys Medwin". Ecouen. 2014-09-02
Vivet Therapeutics S.A.S.. (5/4/17). "Press Release: Vivet Therapeutics Raises €37.5 Million in Series A Financing Round to Advance Novel Gene Therapies for Treating Inherited Metabolic Diseases". Paris. 2017-05-04
Vivalis S.A.. (8/28/12). "Press Release: Vivalis Announces a New EB66 Cell Line Research License Agreement with BioFactura". Nantes & Lyon. 2012-08-28
Vivalis S.A.. (8/21/12). "Press Release: Successful Growth of BioDiem’s Virus in Vivalis EB66 Cell Line". Melbourne & Nantes. 2012-08-21
Vivalis S.A.. (6/20/12). "Press Release: Vivalis Announces a New EB66 Cell Line Commercial License Agreement with Farvet Farmacológicos Veterinarios". 2012-06-20
Vivalis S.A.. (4/8/13). "Press Release: Vivalis Announces a New EB66 Cell Line Research Services and License Option Agreement with GlaxoSmithKline". 2013-04-08
Vivalis S.A.. (3/7/13). "Press Release: Vivalis SA and Intercell AG Shareholders Approved the Proposed Merger of Equals to Create Valneva SE". Nantes & Vienna. 2013-03-07
Vivalis S.A.. (3/29/12). "Press Release: Vivalis 2011 Results. Continuing Growth Momentum". Nantes & Lyon. 2012-03-29
Vivalis S.A.. (3/26/13). "Press Release: The Expanded Development of EB66 Cell Line as Part of the GlaxoSmithKline (GSK) – Texas A&M University System Influenza Vaccine Program in the United States". Nantes & Lyon. 2013-03-26
Vivalis S.A.. (3/26/13). "Press Release: Consolidated 2012 Financial Results". Nantes & Lyon. 2013-03-26
Vivalis S.A.. (3/13/12). "Press Release: Vivalis Announces the Signature of a Broad Collaboration Agreement and Commercial License for the Use of the EB66 Cell Line for the Production of a Monoclonal Antibody". Nantes & Lyon. 2012-03-13
Vivalis S.A.. (2/14/13). "Press Release: 2012 – A Record Year for New EB66 Cell Line Licensing". Nantes. 2013-02-14
Vivalis S.A.. (12/16/12). "Press Release: Proposed Merger of Equals between Vivalis and Intercell. Creation of a European Biotech Leader in Vaccines and Antibodies [Not for Distribution in Australia, Canada, Japan or the United States]". Nantes & Vienna. 2012-12-16
Vivalis S.A.. (1/24/12). "Press Release: Strong Revenue Growth – +112%. Initation of a Third Antibody Discovery Program with Sanofi Pasteur". Nantes & Lyon. 2012-01-24
Vivalis S.A.. (1/23/12). "Press Release: Opening of a New Laboratory Dedicated to the Viva|Screen Antibody Discovery Platform". Nantes, Lyon & Toyama. 2012-01-23
Vivalis S.A.. (1/17/12). "Press Release: Vivalis and Sanofi Pasteur Extend Their 2010 Collaboration and License Contract with a New Human Monoclonal Antibody Discovery Target against a New Infectious Disease". Nantes, Lyon & Toyama. 2012-01-17
Vivalis S.A.. (1/11/10). "Press Release: Vivalis Announces the Strategic Acquisition of Humalys and the Addition of a New Platform for Generating Human Monoclonal Antibodies". Nantes. 2010-01-11
VitamFero S.A.. (9/30/14). "Press Release: VitamFero Successfully Secures Its Third Round of Financing". 2014-09-30
Vexim S.A.. (9/8/14). "Press Release: Vexim Opens U.S. Subsidiary. Office to Support Vexim’s Product Portfolio Launch in the U.S.". Toulouse. 2014-09-08
Vexim S.A.. (9/22/14). "Press Release: Vexim Announces Strong 2014 Half-year Results". Toulouse. 2014-09-22
Vexim S.A.. (4/15/14). "Press Release: Vexim Doubles Its Sales in the 1st Quarter of 2014, to €2.1m". Toulouse. 2014-04-15
Vaxon Biotech S.A.. (12/1/14). "Press Release: Vaxon Biotech Randomizes the 110th Patient in Its Oncology Vaccine Phase IIB Clinical Study in NSCLC. Oncology Vaccine Vx-001 Is the Only One in the World to Use Optimized Cryptic Peptides". Paris. 2014-12-01
Valneva S.E.. (9/27/18). "Press Release: Valneva Raises €50 Million in Oversubscribed Placement Led by US Healthcare Investors [Not for Distribution in the United States, Canada, Australia or Japan]". Saint-Herblain. 2018-09-27
Valneva S.E.. (9/26/18). "Press Release: Valneva Launches a Capital Increase of Approximately €40 Million [Not for Distribution in the United States, Canada, Australia or Japan]". Saint-Herblain. 2018-09-26
Valneva S.E.. (9/20/18). "Press Release: Valneva Announces Extension of Drawdown Period for Its Existing European Investment Bank Loan". Saint-Herblain. 2018-09-20
Valneva S.E.. (8/8/14). "Press Release: Valneva Reports H1 2014 Results, Confirms Full Year Outlook, and Provides Business Update". Lyon. 2014-08-08
Valneva S.E.. (8/27/15). "Press Release: Valneva Announces Two New EB66 Agreements. 7 new EB66 Deals Signed Since the Beginning of the Year". Lyon. 2015-08-27
Valneva S.E.. (8/12/13). "Press Release: Valneva Announces Passing of Management Board Member, Chief Scientific Officer Majid Mehtali". Lyon. 2013-08-12
Valneva S.E.. (8/1/17). "Press Release: Valneva Announces Expansion of its Management Board – Strengthening Senior Management for Future Growth". Lyon. 2017-08-01
Valneva S.E.. (7/4/13). "Press Release: Valneva Announces the Successful Completion of Its €40 Million Capital Increase – Transaction Was Oversubscribed by 146% [Not for US, Canada, Australia, or Japan]". Lyon. 2013-07-04
Valneva S.E.. (7/24/17). "Press Release: Valneva Receives FDA Fast Track Designation for Its Lyme Disease Vaccine Candidate VLA15". Lyon. 2017-07-24
Valneva S.E.. (7/23/15). "Press Release: Valneva and PaxVax Enter into Marketing and Distribution Agreement". Lyon. 2015-07-23
Valneva S.E.. (7/16/13). "Press Release: Valneva Announces a New EB66 Cell Line Research License Agreement with Boehringer Ingelheim". Lyon. 2013-07-16
Valneva S.E.. (7/12/16). "Press Release: European Investment Bank Grants Valneva a €25 Million Loan to Fund R&D Activities". Lyon & Luxembourg. 2016-07-12
Valneva S.E.. (6/22/15). "Press Release: Valneva Takes Direct Control Over Marketing and Distribution of Ixiaro to Increase Margin and Profitability ". Lyon. 2015-06-22
Valneva S.E.. (3/26/15). "Press Release: Valneva Announces Approval of an EB66-based Prototype Influenza Vaccine in Japan". Lyon. 2015-03-26
Valneva S.E.. (3/24/14). "Press Release: Valneva Reports Annual Results 2013. Company Sees First Year of Merger as Operational and Human Success". Lyon. 2014-03-24
Valneva S.E.. (3/24/14). "Press Release: Valneva Announces Continuation of the Phase II/III Clinical Trial for Its Pseudomonas Aeurginosa Vaccine Candidate". Lyon. 2014-03-24
Valneva S.E.. (2/4/15). "Press Release: Valneva Announces the Successful Completion of Its EUR 45 Million Capital Increase [Not for United States, Canada, Australia or Japan]". Lyon. 2015-02-04
Valneva S.E.. (2/26/18). "Press Release: Emergent BioSolutions and Valneva Initiate Phase 1 Clinical Study to Evaluate Vaccine Candidate against Zika Virus". Gaithersburg, MD & Lyon. 2018-02-26
Valneva S.E.. (2/24/16). "Press Release: Valneva Posts 96% Revenue Growth in 2015, Forecasts 2016 Revenues of €90 to €100 Million". Lyon. 2016-02-24
Valneva S.E.. (2/23/17). "Press Release: Valneva Reports Strong Q4 and FY 2016 Business Performance, Expects Further Growth in Sales and EBITDA, R&D Progress in 2017". Lyon. 2017-02-23
Valneva S.E.. (12/6/18). "Press Release: Valneva and Hookipa Sign a Collaboration and Manufacturing Agreement". Saint-Herblain & Vienna. 2018-12-06
Valneva S.E.. (12/21/18). "Press Release: Valneva Awarded FDA Fast Track Designation for Chikungunya Vaccine Candidate". Saint-Herblain. 2018-12-21
Valneva S.E.. (12/17/18). "Press Release: Valneva Initiates Phase 2 Clinical Development For Its Lyme Disease Vaccine Candidate". Saint-Herblain. 2018-12-17
Valneva S.E.. (12/15/16). "Press Release: Valneva Confirms Closing of Private Placement in Connection with €15.2m Investment by MVM Life Science Partners". Lyon. 2016-12-15
Valneva S.E.. (12/11/14). "Press Release: Valneva and BliNK Therapeutics Announce Launch of New Biotech Company in Innovative Antibody Discovery. New company Has Already Secured First Round of Financing". Louvain-la-Neuve. 2014-12-11
Valneva S.E.. (12/10/14). "Press Release: Valneva Announces Publication of First Phase II Data of Tuberculosis Vaccine Candidate Formulated with IC31® Adjuvant. Clinical Trial in HIV-infected Adults Showed Good Safety and Immunogenicity". Lyon. 2014-12-10
Valneva S.E.. (12/1/16). "Press Release: Leading Healthcare Investor MVM Life Science Partners Acquires 7.5% Shareholding in Valneva". Lyon. 2016-12-01
Valneva S.E.. (11/9/17). "Press Release: Valneva Reports Strong Operational Performance for the First Nine Months of 2017". Lyon. 2017-11-09
Valneva S.E.. (11/9/16). "Press Release: Valneva Reports Strong Business Performance in First Nine Months, Company Increases Financial Guidance for Full Year 2016". Lyon. 2016-11-09
Valneva S.E.. (11/7/17). "Press Release: Valneva Signs $39.6 Million Ixiaro Supply Contract with US Government". Lyon. 2017-11-07
Valneva S.E.. (11/6/14). "Press Release: Valneva Announces Best Quarterly Results Since Vivalis/Intercell Merger, Meets Business Objectives amd Reconfirms Full Year Outlook". Lyon. 2014-11-06
Valneva S.E.. (11/5/13). "Press Release: Valneva Records Highest Ixiaro/Jespect Sales in Q3 2013, Confirms Full Year Outlook, and Provides R&D Update for Pseudomonas Vaccine Candidate". Lyon. 2013-11-05
Valneva S.E.. (11/10/15). "Press Release: Valneva Reports a Strong Quarter Marked by Key Successes in its Strategic Execution and a Solid Financial Performance". Lyon. 2015-11-10
Valneva S.E.. (1/7/19). "Press Release: Valneva Reports Positive Phase 1 Interim Results for Its Chikungunya Vaccine Candidate". Saint-Herblain. 2019-01-07
Valneva S.E.. (1/7/19). "Press Release: Valneva Announces Its Intention to Delist from the Vienna Stock Exchange. Trading Will Be Centralized on Euronext Paris". Saint-Herblain. 2019-01-07
Valneva S.E.. (1/5/17). "Press Release: Valneva Announces a New Research License Agreement with MSD Animal Health for the Development of Vaccines in the EB66 Cell Line". Lyon. 2017-01-05
Valneva S.E.. (1/29/15). "Press Release: Valneva Grants Exclusive Worldwide License to Immune Targeting Systems for the Development of Hepatitis B Vaccines in Combination with the IC31 Adjuvant". Lyon. 2015-01-29
Valbiotis S.A.. (3/6/18). "Press Release: LpD64 Acts on Alterations of the Microbiota Involved in the Development of Obesity". La Rochelle. 2018-03-06
Valbiotis S.A.. (3/15/18). "Press Release: Valbiotis Obtains Strategic Patent for Valedia in the United States". La Rochelle. 2018-03-15
UroMems. (11/15/16). "Press Release: UroMems Closes €14m Financing to Develop Its Smart Artificial Urinary Sphincter to Market". Grenoble. 2016-11-15
University of Montreal. (12/18/13). "Press Release: Domain Therapeutics, Université de Montréal, IRICoR and McGill University Sign New Licensing and Partnership Agreement on G-Protein Coupled Receptor Biosensor Technology". Strasbourg & Montréal, ON. 2013-12-19
Universal Medica Group. (5/3/17). "Press Release: Acquisition of EuroPharma by Universal Medica Group". 2017-05-03
TxCell S.A.. (9/5/16). "Press Release: TxCell to Present at the 18th Annual Rodman & Renshaw Global Investment Conference on September 13, 2016". Valbonne. 2016-09-05
TxCell S.A.. (9/28/15). "Press Release: TxCell to Present Its Cellular Immunotherapy Developments at Leading Investor Conferences". Valbonne. 2015-09-28
TxCell S.A.. (9/22/15). "Press Release: Financial Results for the First Half of 2015". Valbonne. 2015-09-22
TxCell S.A.. (8/3/16). "Press Release: TxCell Announces the Effective Implementation of the Convertible Notes with Warrants (OCABSA) Financing and the Issue of a First Tranche for an Amount of €3 Million in Nominal Value [Not for US, CA, AU, JP]". Valbon 2016-08-03
TxCell S.A.. (8/24/16). "Press Release: TxCell Appoints Biogen’s Dr. Olivier Danos, Pioneer in Gene Therapy for Neurological Disorders, to Its Scientific Advisory Board". Valbonne. 2016-08-24
TxCell S.A.. (8/24/15). "Press Release: TxCell Consortium Granted €1.28 Million for TRUST Project on Process and Clinical Development of Col-Treg for Autoimmune Uveitis Treatment". Valbonne. 2015-08-24
TxCell S.A.. (7/9/18). "Press Release: TxCell Exercises In-license Option to the University of British Columbia's Intellectual Property Rights of the HLA-A2 CAR-Treg Program". Valbonne. 2018-07-09
TxCell S.A.. (7/27/16). "Press Release: TxCell – Financial Information for the 2nd Quarter of 2016". Valbonne. 2016-07-27
TxCell S.A.. (7/26/17). "Press Release: TxCell – Financial Information for the 2nd Quarter of 2017". Valbonne. 2017-07-26
TxCell S.A.. (6/24/15). "Press Release: TxCell Announces a Temporary Partial Hold of Activities at its Pilot Manufacturing Unit. Company Expects Only Potential Limited Impact on Clinical Product Timeline". Valbonne. 2015-06-24
TxCell S.A.. (6/21/18). "Press Release: First in Vivo Proof-of-Concept Data with CD8+ CAR-Treg Presented at FOCIS 2018". Valbonne. 2018-06-21
TxCell S.A.. (6/21/16). "Press Release: TxCell Exercises Option from Weizmann Institute of Science Following Effective Grant of Broad CAR-Treg Patent in Europe". Valbonne. 2016-06-21
TxCell S.A.. (6/19/17). "Press Release: TxCell Appoints Lentigen Technology, Inc. to Manufacture the Lentiviral Vector for Its First CAR-Treg Program in Transplant Rejection". Valbonne. 2017-06-19
TxCell S.A.. (6/17/16). "Press Release: TxCell Implements a New Financing Contract of up to €20 Million in Nominal Value through Convertible Notes with Warrants (OCABSA) [Not for distribution in the Unites States, Canada, Australia and Japan]". Valbonne. 2016-06-17
TxCell S.A.. (6/1/16). "Press Release: TxCell and the Lübeck Institute of Experimental Dermatology Launch Collaboration to Develop CAR-Tregs in Bullous Pemphigoid". Valbonne. 2016-06-01
TxCell S.A.. (5/31/18). "Press Release: TxCell Names Lonza as Its CAR-Treg Cellular Product Manufacturer". Valbonne & Basel. 2018-05-31
TxCell S.A.. (5/25/16). "Press Release: TxCell Obtains Authorization from European Regulatory Authorities to Restart Ovasave Phase IIb Clinical Trial". Valbonne. 2016-05-25
TxCell S.A.. (5/2/17). "Press Release: TxCell and Inserm Collaborate to Develop New CAR-Tregs in Transplantation and Multiple Sclerosis". Valbonne & Nantes. 2017-05-02
TxCell S.A.. (4/28/15). "Press Release: TxCell Appoints Stéphane Boissel as Chief Executive Officer and Promotes Miguel Forte to Chief Operating Officer". Valbonne. 2015-04-28
TxCell S.A.. (4/25/18). "Press Release: TxCell – Financial Information for the 1st Quarter of 2018 and Availability of the 2017 Registration Document (document de référence)". Valbonne. 2018-04-25
TxCell S.A.. (4/25/16). "Press Release: TxCell and Ospedale San Raffaele Launch Collaboration for the Development of CAR-Tregs in Lupus Nephritis". Valbonne & Milan. 2016-04-25
TxCell S.A.. (4/25/16). "Press Release: Letter to Shareholders – from Stéphane Boissel, CEO of TxCell April 25, 2016". Valbonne & Milan. 2016-04-25
TxCell S.A.. (4/23/15). "Press Release: TxCell and Trizell Amend Collaboration Agreement to Accelerate Ovasave Development". Valbonne. 2015-04-23
TxCell S.A.. (4/20/16). "Press Release: Financial Information for the 1st Quarter of 2016". Valbonne. 2016-04-20
TxCell S.A.. (4/14/14). "Press Release: TxCell Completes IPO on Euronext, Raising EUR 16.2 Million [only for relevant persons]". Valbonne. 2014-04-14
TxCell S.A.. (3/9/17). "Press Release: TxCell 2016 Financial Results". Valbonne. 2017-03-09
TxCell S.A.. (3/31/16). "Press Release: TxCell Appoints Its Global Scientific Advisory Board (“SAB”) Led by Professor Zelig Eshhar as Chairman". Valbonne. 2016-03-31
TxCell S.A.. (3/15/16). "Press Release: TxCell Appoints PCT as Its US Manufacturing Partner". Valbonne. 2016-03-15
TxCell S.A.. (3/10/16). "Press Release: TxCell 2015 Results and Update on Strategy and Outlook". Valbonne. 2016-03-10
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15  next pagenext page



Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Partnering Opens 600x60px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

» top